ADC Therapeutics SA: 2025 Annual Performance and Strategic Outlook

For investors following the innovative biotechnology sector, ADC Therapeutics SA (NYSE: ADCT) presents its performance and strategic direction for the fiscal year ended December 31, 2025. This comprehensive review offers key insights into the company's journey.

1. Business Overview

ADC Therapeutics SA, a Switzerland-based biotechnology company, develops and commercializes antibody-drug conjugates (ADCs) to treat cancer. Its flagship commercial product, ZYNLONTA (loncastuximab tesirine-lpyl), has received FDA approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company also advances Camidanalamab Tesirine (Cami), a pipeline candidate currently in Phase 3 clinical trials for relapsed or refractory peripheral T-cell lymphoma (PTCL). In fiscal year 2025, ADC Therapeutics focused on ZYNLONTA's continued commercialization, strategic restructuring, and significant capital-raising efforts.

2. Financial Performance

ADC Therapeutics reported total revenue of $125.7 million for fiscal year 2025, an increase from $105.2 million in 2024. Increased sales of their lead product, ZYNLONTA, primarily drove this growth. Despite rising revenue, the company recorded a net loss of $(210.5) million in 2025, an improvement from the $(235.1) million net loss in 2024. This reduced net loss demonstrates efforts to manage operating expenses, even as significant R&D and commercialization costs continue. Gross profit reached $80.4 million, translating to a gross margin of approximately 64%. As of June 30, 2025, the market value of common stock held by non-affiliates was approximately $136.4 million.

3. Risk Factors

Investors should be aware of several significant risks:

• Customer Concentration: A limited number of wholesale distributors—McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health—handle a substantial portion of ZYNLONTA sales. Losing any of these key customers or significant changes in their purchasing patterns could materially impact revenue.
• Liquidity and Going Concern: The company's history of net losses and reliance on external financing raise concerns about its ability to generate sufficient cash flow. The risk exists that the company may not secure additional financing on favorable terms, or at all, potentially affecting its ability to continue operations.
• Product Dependence: The company's current and projected revenue heavily depends on ZYNLONTA. Issues with its commercialization, market acceptance, competition, or regulatory status could severely impact financial performance.
• Clinical Development and Regulatory Risk: The success of pipeline candidates like Cami is subject to the inherent risks of clinical trials, including failures, unexpected safety issues, and delays in regulatory approvals.
• Competition: The oncology market, particularly for lymphoma treatments, is highly competitive, featuring established players and emerging therapies.
• Intellectual Property: The company's success depends on its ability to protect its intellectual property, including patents for ZYNLONTA and Cami.
• Financial Restatement Impact: While addressed, the prior financial restatement could impact investor confidence and potentially lead to further scrutiny or adjustments.

4. Management Discussion and Analysis (MD&A) Highlights

Fiscal year 2025 saw ADC Therapeutics implement strategic actions to optimize operations and strengthen its financial position.

A significant event was the restatement of previously issued financial statements for 2023 and 2022. This primarily addressed issues with revenue recognition for ZYNLONTA sales and the accounting for certain warrants. The company has since resolved these issues. As a "non-accelerated filer" and "smaller reporting company," ADCT benefits from less stringent reporting requirements.

The company launched a significant restructuring initiative to streamline operations, reduce costs, and prioritize key programs. This included a workforce reduction impacting approximately 17% of employees and is projected to generate annual cost savings of $25-30 million, mainly from reduced R&D and G&A expenses. The restructuring incurred a one-time charge of approximately $8.5 million for employee severance and related costs. These efforts contributed to the year's reduced net loss.

To bolster its financial position and fund ongoing operations, the company actively engaged in capital markets. Key financing activities included a private placement in June 2025 raising $75.0 million, another private placement in October 2025 raising $50.0 million, an equity offering in May 2024 raising $60.0 million, and a public stock offering in August 2024 raising $45.0 million. While crucial, these capital infusions increased shares outstanding, leading to dilution for existing shareholders.

Management's strategic focus remains on maximizing ZYNLONTA's commercial potential by expanding its market reach and exploring its use in earlier lines of therapy and combination regimens. Concurrently, the company advances its most promising pipeline assets, particularly Camidanalamab Tesirine (Cami), towards regulatory submission. Leadership continues to use equity incentive plans as vital tools to attract, retain, and motivate key talent, aligning employee interests with shareholder value creation.

Critical Accounting Policies and Estimates: The company prepares its financial statements following U.S. GAAP, which requires management to make estimates and judgments affecting reported amounts of assets, liabilities, revenues, and expenses. Key areas demanding significant judgment include revenue recognition (especially for product sales and collaboration agreements), valuation of stock-based compensation, and assessing the recoverability of deferred tax assets. While management believes these estimates are reasonable, actual results could differ.

5. Financial Health

As of December 31, 2025, ADC Therapeutics held cash and cash equivalents of $98.2 million, down from $145.6 million at the end of 2024. This decrease reflects ongoing operating losses and investments.

The company holds secured debt through a term loan facility with an outstanding principal balance of $150.0 million, alongside a revolving credit facility, which offers additional liquidity. These debt instruments come with specific covenants and interest rates that influence financial flexibility.

Additionally, various warrants remain outstanding, including those held by Deerfield and HCR. Their exercise could lead to further equity dilution. As of March 2, 2026, approximately 127 million common shares were outstanding.

The company projects its current cash and anticipated revenues will fund operations into the third quarter of 2026, underscoring the ongoing need for capital management and potential future financing.

6. Future Outlook

Management projects continued commercial growth for ZYNLONTA in 2026, with revenue guidance set at $130-$150 million. Key upcoming milestones include potential data readouts from ongoing clinical trials for ZYNLONTA in combination therapies and the advancement of Cami's Phase 3 trial. The company's strategy focuses on driving ZYNLONTA's market penetration, advancing Cami towards regulatory submission, and maintaining disciplined expense management to improve financial performance. Subsequent events in early 2026, such as ongoing discussions for potential partnerships or additional financing, will critically shape the near-term future.

7. Competitive Position

ADC Therapeutics operates within the highly competitive oncology therapeutic space, specifically targeting blood cancers (hematological malignancies). ZYNLONTA competes with other approved therapies for relapsed/refractory DLBCL, including CAR T-cell therapies, other ADCs, and traditional chemotherapy regimens. The company aims to differentiate ZYNLONTA through its unique mechanism of action and clinical profile. If approved, Cami would enter a competitive landscape for PTCL, where developers continuously introduce novel therapies. The company's ability to demonstrate superior efficacy, safety, and patient convenience will be critical for market penetration.

8. Market Trends and Regulatory Environment

As a therapeutics company, ADC Therapeutics is significantly influenced by evolving market trends in oncology, especially the growing interest and investment in ADC technology. The regulatory landscape remains stringent, with health authorities like the FDA and EMA continuously scrutinizing drug development, approval, and post-market surveillance. Pricing pressures and reimbursement policies for oncology drugs also pose ongoing challenges, requiring strategic engagement with payers and healthcare systems. The rapid pace of scientific innovation in cancer treatment demands continuous R&D investment to remain competitive.